Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:21PM ET
270.60
Dollar change
+1.23
Percentage change
0.45
%
IndexS&P 500 P/E29.39 EPS (ttm)9.21 Insider Own2.14% Shs Outstand51.34M Perf Week-1.04%
Market Cap13.90B Forward P/E21.79 EPS next Y12.42 Insider Trans-2.89% Shs Float50.25M Perf Month5.40%
Income474.62M PEG3.20 EPS next Q2.06 Inst Own101.29% Short Float3.16% Perf Quarter13.30%
Sales4.13B P/S3.36 EPS this Y3.14% Inst Trans3.22% Short Ratio2.84 Perf Half Y38.81%
Book/sh70.06 P/B3.86 EPS next Y12.87% ROA6.01% Short Interest1.59M Perf Year41.02%
Cash/sh5.50 P/C49.17 EPS next 5Y9.19% ROE14.44% 52W Range161.65 - 275.00 Perf YTD14.46%
Dividend Est.- P/FCF38.03 EPS past 5Y14.84% ROI7.12% 52W High-1.60% Beta1.39
Dividend TTM- Quick Ratio1.16 Sales past 5Y12.89% Gross Margin33.56% 52W Low67.40% ATR (14)6.69
Dividend Ex-Date- Current Ratio1.52 EPS Y/Y TTM-3.17% Oper. Margin15.82% RSI (14)63.54 Volatility2.06% 2.68%
Employees21800 Debt/Eq0.87 Sales Y/Y TTM3.86% Profit Margin11.49% Recom1.94 Target Price267.48
Option/ShortYes / Yes LT Debt/Eq0.85 EPS Q/Q-0.65% Payout0.00% Rel Volume0.59 Prev Close269.37
Sales Surprise2.24% EPS Surprise2.42% Sales Q/Q-7.85% EarningsFeb 14 BMO Avg Volume559.09K Price270.60
SMA202.29% SMA5011.78% SMA20027.27% Trades Volume298,625 Change0.45%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Downgrade Guggenheim Buy → Neutral
Sep-13-23Initiated TD Cowen Market Perform $212
Jul-10-23Downgrade Citigroup Buy → Neutral $260 → $225
Feb-23-23Upgrade Guggenheim Neutral → Buy $255
Jan-12-23Downgrade Jefferies Buy → Hold
Sep-30-22Upgrade Jefferies Hold → Buy $240
Aug-25-22Initiated Credit Suisse Outperform $285
Aug-04-22Downgrade Morgan Stanley Overweight → Equal-Weight $350 → $250
May-24-22Initiated Guggenheim Neutral
Apr-25-22Downgrade Jefferies Buy → Hold $370 → $280
Mar-27-24 08:00AM
Mar-26-24 09:39AM
Mar-23-24 09:00AM
Mar-21-24 08:00AM
Mar-15-24 11:30AM
10:30AM Loading…
10:30AM
Mar-14-24 09:46AM
08:00AM
Mar-12-24 08:00AM
12:11AM
Mar-07-24 12:27PM
Mar-01-24 11:32PM
Feb-29-24 02:00AM
Feb-26-24 08:41AM
Feb-21-24 10:40AM
08:00AM Loading…
08:00AM
Feb-20-24 01:15PM
08:08AM
Feb-15-24 01:00PM
10:54AM
12:38AM
Feb-14-24 08:06PM
09:30AM
09:30AM
08:09AM
07:19AM
07:00AM
Feb-13-24 08:20AM
Feb-09-24 09:15AM
Feb-01-24 10:08AM
08:00AM Loading…
Jan-29-24 08:00AM
Jan-27-24 09:00AM
Jan-24-24 04:30PM
Jan-23-24 04:30PM
Jan-18-24 09:10AM
Jan-16-24 08:00AM
08:00AM
Jan-12-24 02:02PM
09:00AM
Jan-08-24 08:00AM
Jan-02-24 09:00AM
Dec-19-23 08:01AM
Dec-18-23 08:00AM
Dec-13-23 08:29AM
Dec-12-23 08:00AM
Dec-08-23 11:30AM
Dec-07-23 01:53PM
Dec-05-23 07:29AM
Dec-02-23 01:05AM
Nov-29-23 07:57AM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 03:04AM
Nov-20-23 08:34PM
Nov-17-23 06:45PM
08:40AM
Nov-16-23 12:59PM
08:00AM
Nov-13-23 09:04AM
Nov-10-23 12:11PM
Nov-09-23 05:14PM
08:00AM
01:33AM
Nov-08-23 03:20PM
10:59AM
09:30AM
08:54AM
08:26AM
07:06AM
07:00AM
Nov-06-23 10:27AM
Nov-01-23 10:01AM
09:13AM
Oct-25-23 08:06PM
Oct-24-23 12:10PM
Oct-23-23 10:10AM
Oct-19-23 08:00AM
Oct-16-23 08:30AM
08:00AM
Oct-11-23 08:00AM
Oct-10-23 09:10AM
Oct-05-23 12:55PM
Oct-02-23 11:35AM
Sep-27-23 12:04PM
Sep-26-23 08:02AM
08:00AM
Sep-25-23 11:40AM
08:00AM
Sep-21-23 11:36AM
Sep-20-23 08:30AM
Sep-18-23 12:03PM
Sep-15-23 08:36AM
Sep-14-23 08:00AM
Sep-12-23 11:33AM
Sep-11-23 08:00AM
Sep-08-23 11:30AM
Sep-06-23 03:02PM
10:35AM
08:00AM
Aug-30-23 07:32PM
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knell Michael GunnarCSVP&Chief Accounting OfficerMar 08 '24Sale267.52808216,1567,024Mar 11 04:42 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerMar 04 '24Sale261.052,750717,8907,832Mar 05 04:54 PM
Creamer Victoria LEVP & Chief People OfficerFeb 29 '24Sale253.705,0001,268,50013,550Mar 01 05:37 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentFeb 29 '24Sale253.453,786959,5454,792Mar 04 04:09 PM
Barbo William DCorporate Executive VP & CCOFeb 22 '24Sale248.504,0501,006,42522,879Feb 23 04:57 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentFeb 15 '24Option Exercise144.675,882850,9498,478Feb 20 05:32 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentFeb 15 '24Sale241.205,8821,418,7672,596Feb 20 05:32 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 15 '24Sale238.93838200,22324,620Feb 20 05:20 PM
FOSTER JAMES CChairman, President and CEOJan 29 '24Option Exercise144.6717,4362,522,466227,827Jan 31 04:59 PM
Girshick BirgitCorporate Executive VP & COOJan 10 '24Option Exercise215.195,9161,273,06450,365Jan 11 04:09 PM
Creamer Victoria LEVP & Chief People OfficerDec 14 '23Option Exercise136.705,526755,38822,032Dec 18 04:07 PM
Creamer Victoria LEVP & Chief People OfficerDec 14 '23Sale225.005,5261,243,35016,506Dec 18 04:07 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 30 '23Sale197.731,850365,80023,133Dec 01 04:10 PM
Girshick BirgitCorporate Executive VP & COONov 20 '23Buy187.821,322248,29844,449Nov 21 05:07 PM
FOSTER JAMES CChairman, President and CEONov 14 '23Buy178.055,6201,000,641202,643Nov 15 09:23 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 09 '23Option Exercise144.679,1281,320,54834,111Nov 13 04:12 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 09 '23Sale173.489,1281,583,52224,983Nov 13 04:12 PM
WALLMAN RICHARD FDirectorAug 24 '23Buy198.791,000198,7861,000Aug 29 04:23 PM
Barbo William DCorporate Executive VP & CCOAug 10 '23Option Exercise144.675,511797,2769,103Aug 14 04:17 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 10 '23Option Exercise144.671,471212,81011,411Aug 14 04:15 PM
Barbo William DCorporate Executive VP & CCOAug 10 '23Sale217.245,7631,251,9543,592Aug 14 04:17 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 10 '23Sale216.541,471318,5309,940Aug 14 04:15 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 10 '23Sale216.52700151,56424,983Aug 14 04:11 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15 '23Sale190.3934565,68524,026May 16 02:18 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 12 '23Sale193.03959185,11624,371May 15 02:49 PM
MASSARO GEORGEDirectorMay 11 '23Sale193.4328855,7084,964May 15 02:42 PM